ORBi: Ribbens Clio - Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment

Reference : Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship wi...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Rheumatology
	To cite this reference:	http://hdl.handle.net/2268/72419

Title :	Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment
Language :	English
Author, co-author :	Ribbens, Clio [Université de Liège - ULg > > Rhumatologie >]
	Martin y Porras, M. [ > > ]
	Franchimont, N. [ > > ]
	Kaiser, Marie-Joëlle [Université de Liège - ULg > > Rhumatologie >]
	Jaspar, J. M. [ > > ]
	Damas, Pierre [Université de Liège - ULg > > Soins intensifs >]
	Houssiau, F. A. [ > > ]
	Malaise, Michel [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >]
Publication date :	2002
Journal title :	Annals of the Rheumatic Diseases
Publisher :	BMJ Group
Volume :	61
Issue/season :	2
Pages :	161-166
Audience :	International
ISSN :	0003-4967
e-ISSN :	1468-2060
City :	London
Country :	United Kingdom
Keywords :	[en] Biological Markers ; Glucocorticoids ; Prednisolone ; C-Reactive Protein ; Matrix Metalloproteinase 3
Abstract :	[en] OBJECTIVE: To determine matrix metalloproteinase-3 (MMP-3) serum levels in patients with rheumatic diseases and to study the relation between MMP-3 and C reactive protein (CRP) levels. METHODS: MMP-3 serum levels were determined by enzyme linked immunosorbent assay (ELISA) in (a) patients with active inflammatory rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis, polymyalgia rheumatica, acute crystal arthritis, and ankylosing spondylitis; (b) patients with active inflammatory systemic diseases: cutaneo-articular or renal systemic lupus erythematosus (SLE), systemic sclerosis, and vasculitides; (c) patients with non-inflammatory rheumatic diseases: osteoarthritis and fibromyalgia; (d) critically ill patients without rheumatic diseases, representing an acute inflammatory control group; (e) healthy controls. RESULTS: MMP-3 serum levels were significantly increased in patients with active RA, psoriatic arthritis, and polymyalgia rheumatica, whether treated or not by corticosteroids, and in female patients with acute crystal arthritis. MMP-3 serum levels were normal in steroid-free patients with active cutaneo-articular or renal SLE, systemic sclerosis, and vasculitides but were significantly increased in steroid treated patients. MMP-3 levels were normal in fibromyalgia, osteoarthritis, ankylosing spondylitis, and acute inflammatory controls. MMP-3 was significantly correlated with CRP in RA (r=0.5, p=0.0004) but not in any of the other disease groups. CONCLUSIONS: MMP-3 serum levels are increased in inflammatory rheumatic diseases characterised by joint synovitis, such as RA, polymyalgia rheumatica, psoriatic arthritis, and acute crystal arthritis-that is, whether the diseases are acute or chronic, erosive or not. They are normal in SLE, systemic sclerosis, and vasculitides as well as in non-rheumatic inflammatory controls, but are significantly increased by steroids. These data strongly suggest that serum MMP-3 reflects synovial inflammation.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/72419

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	Malaise_2002_AnnRheumDis_161-166.pdf		Publisher postprint	1.29 MB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5